

Electronic supplementary material

ESM Table 2 Summary of treatment-emergent adverse events by System Organ Class (SOC) that occurred with an incidence of at least 5% in the insulin glargine group, and that differed in incidence between treatment groups by 1% or more (safety population)

SOC	Data for insulin glargine difference ≥1% vs NPH insulin		SOC	Data for NPH insulin difference ≥1% vs insulin glargine	
	Insulin glargine (<i>n</i> =514)	NPH insulin (<i>n</i> =503)		Insulin glargine (<i>n</i> =514)	NPH insulin (<i>n</i> =503)
Cataract	93 (18.1)	80 (15.9)	Upper respiratory tract infection	149 (29.0)	169 (33.6)
Bronchitis	78 (15.2)	71 (14.1)	Oedema peripheral	103 (20.0)	114 (22.7)
Cough	62 (12.1)	37 (7.4)	Arthralgia	73 (14.2)	81 (16.1)
Muscle spasms	47 (9.1)	35 (7.0)	Musculoskeletal pain	44 (8.6)	51 (10.1)
Nausea	44 (8.6)	34 (6.8)	Hypoglycaemia	36 (7.0)	48 (9.5)
Gastroenteritis viral	41 (8.0)	30 (6.0)	Chest pain	32 (6.2)	41 (8.2)
Gastroesophageal reflux disease	41 (8.0)	34 (6.8)	Pneumonia	30 (5.8)	36 (7.2)
Fatigue	41 (8.0)	30 (6.0)	Pharyngolaryngeal pain	29 (5.6)	35 (7.0)
Dizziness	38 (7.4)	29 (5.8)	Osteoarthritis	29 (5.6)	37 (7.4)
Hyperlipidaemia	37 (7.2)	22 (4.4)	Dyspnea	27 (5.3)	33 (6.6)
Sensory disturbance	27 (5.3)	17 (3.4)	Neoplasms	57 (11.1)	62 (12.3)
Anxiety	26 (5.1)	18 (3.6)			

Data are *n* (%)